Podcast appearances and mentions of mark socinski

CME credits: 0.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/advancing-alk-inhibition-into-early-stage-nsclc-integrating-biomarker-driven-therapies-to-reduce-recurrence-risk-post-resection/27056/ This animated podcast explores the evolving role of ALK inhibitors in managing early-stage non-small cell lung cancer (NSCLC). Dr. Mark Socinski discusses molecular profiling as a cornerstone for identifying ALK fusion–positive cases and highlights clinical data from pivotal trials. He also addresses the challenges of treatment adherence, toxicity management, and the importance of surrogate endpoints in early-stage disease. The discussion concludes with key takeaways on integrating targeted therapies into standard care for early-stage resectable NSCLC.=

October 26, 2022 - Dr Mark Socinski & Tiffany

This episode features Dr. Mark Socinski, Executive Director (Thoracic Cancer) & Medical Oncologist at AdventHealth. Here, he discusses his background & work with AdventHealth, his new research recently published in JAMA that finds having an inflammatory side effect with advanced non-small cell lung cancer (NSCLC) might not be such a bad thing, how this research can help with survival rates, if this may extend into other areas of cancer, and more.

CME credits: 0.25 Valid until: 17-04-2024 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-personalizing-treatment-in-nsclc-locally-advanced-disease-stage-iiibc/15139/ The clinical value of adding immunotherapy together with chemoradiation in locally advanced non-small cell lung cancer (NSCLC) has been evident since 2017. This concept has been extended through the emergence of key clinical trials, such as KEYNOTE-799, which includes both squamous and non-squamous subsets. In fact, the coalescence of chemoradiation and immunotherapy has begun to not only push up overall survival, but to also improve cure rates with manageable toxicity. But as the landscape rapidly changes, it becomes increasingly difficult to link evolving data to clinical practice. Join Drs. Mark Socinski and Kristin Higgins as they parse the key trials and offer insights that will help you provide better care, and possibly more hope, for your patients with locally advanced NSCLC.=

CME credits: 0.25 Valid until: 17-04-2024 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-personalizing-treatment-in-nsclc-early-stage-disease-stage-i-iiia/15138/ The optimal management of non-small cell lung cancer (NSCLC) has fundamentally changed. Targeted agents, mono and combination immunotherapy, and immunochemotherapy options continue to emerge. You also need to factor in new and investigational neoadjuvant and adjuvant regimens. So how do you determine which patients will benefit most within this new landscape of options? Join Drs. Mark Socinski and Patrick Forde as they address these questions and provide a measure of order in the chaos.=

October 26, 2022 - Dr Mark Socinski & Tiffany

CME credits: 0.25 Valid until: 15-07-2023 Claim your CME credit at https://reachmd.com/programs/cme/personalizing-nsclc-the-optimal-applicability-of-ngs-and-liquid-biopsy/13834/ There are new targeted therapies that are now approved for the treatment of advanced non-small cell lung cancer. Dr. Mark Socinski & Dr. Marie Suga discuss evolving diagnostic approaches and best practices for selecting the right therapy for patients with NSCLC.

CME credits: 0.25 Valid until: 15-07-2023 Claim your CME credit at https://reachmd.com/programs/cme/personalizing-nsclc-the-optimal-applicability-of-ngs-and-liquid-biopsy/13834/ There are new targeted therapies that are now approved for the treatment of advanced non-small cell lung cancer. Dr. Mark Socinski & Dr. Marie Suga discuss evolving diagnostic approaches and best practices for selecting the right therapy for patients with NSCLC.

CME credits: 0.25 Valid until: 30-12-2022 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-guidelines-and-the-future-direction-of-immunotherapy-in-nsclc/13165/ The therapeutic landscape for the first-line treatment of non-driver metastatic NSCLC has become complex and, in some cases, controversial. Based on PD-L1 status, do you know which patients should receive immune checkpoint inhibitor (ICI) monotherapy and when ICI should be combined with chemotherapy? Join Drs. Mark Socinski and Edward Garon as they focus on the intricacies associated with making these therapeutic choices, while also looking at future immunotherapeutic opportunities in the neoadjuvant and adjuvant settings.

CME credits: 0.25 Valid until: 30-12-2022 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-clinical-case-challenges-in-nsclc/13181/ With the availability of more immunotherapies for the management of first-line metastatic NSCLC, PD-L1 status takes on greater importance in determining which approach is best for each patient. Follow along as Dr. Mark Socinski and Dr. Benjamin Levy discuss the factors they use when considering either an immuno-monotherapy or immunotherapy plus chemotherapy approach, and how they monitor for and manage immunotherapy-related adverse events.

CME credits: 0.25 Valid until: 30-12-2022 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-guidelines-and-the-future-direction-of-immunotherapy-in-nsclc/13165/ The therapeutic landscape for the first-line treatment of non-driver metastatic NSCLC has become complex and, in some cases, controversial. Based on PD-L1 status, do you know which patients should receive immune checkpoint inhibitor (ICI) monotherapy and when ICI should be combined with chemotherapy? Join Drs. Mark Socinski and Edward Garon as they focus on the intricacies associated with making these therapeutic choices, while also looking at future immunotherapeutic opportunities in the neoadjuvant and adjuvant settings.

CME credits: 0.25 Valid until: 30-12-2022 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-integration-of-immune-checkpoint-inhibitors-as-initial-therapy-for-advanced-disease/13147/ Medical innovation in the treatment of lung cancer is at an all-time high. However, the gap between recent developments and their adoption into clinical practice continues to expand for community oncologists as the plethora of scientific and clinical data for the treatment of NSCLC rapidly emerges. Dr. Mark Socinski and Dr. Sandip Patel go through the selection and management of immune checkpoint inhibitors for patients with advanced NSCLC who do not have an actionable mutation.

CME credits: 0.25 Valid until: 30-12-2022 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-integration-of-immune-checkpoint-inhibitors-as-initial-therapy-for-advanced-disease/13147/ Medical innovation in the treatment of lung cancer is at an all-time high. However, the gap between recent developments and their adoption into clinical practice continues to expand for community oncologists as the plethora of scientific and clinical data for the treatment of NSCLC rapidly emerges. Dr. Mark Socinski and Dr. Sandip Patel go through the selection and management of immune checkpoint inhibitors for patients with advanced NSCLC who do not have an actionable mutation.

Host: Mark Socinski, MD Guest: Sandip Patel, MD Medical innovation in the treatment of lung cancer is at an all-time high. However, the gap between recent developments and their adoption into clinical practice continues to expand for community oncologists as the plethora of scientific and clinical data for the treatment of NSCLC rapidly emerges. Dr. Mark Socinski and Dr. Sandip Patel go through the selection and management of immune checkpoint inhibitors for patients with advanced NSCLC who do not have an actionable mutation.

Host: Mark Socinski, MD Guest: Benjamin Levy, MD With the availability of more immunotherapies for the management of first-line metastatic NSCLC, PD-L1 status takes on greater importance in determining which approach is best for each patient. Follow along as Dr. Mark Socinski and Dr. Benjamin Levy discuss the factors they use when considering either an immuno-monotherapy or immunotherapy plus chemotherapy approach, and how they monitor for and manage immunotherapy-related adverse events.

CME credits: 0.25 Valid until: 30-12-2022 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-clinical-case-challenges-in-nsclc/13181/ With the availability of more immunotherapies for the management of first-line metastatic NSCLC, PD-L1 status takes on greater importance in determining which approach is best for each patient. Follow along as Dr. Mark Socinski and Dr. Benjamin Levy discuss the factors they use when considering either an immuno-monotherapy or immunotherapy plus chemotherapy approach, and how they monitor for and manage immunotherapy-related adverse events.

CME credits: 0.25 Valid until: 17-12-2022 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-applying-the-right-therapy-to-the-right-patient-in-ret-positive-nsclc/13130/ With an expanding arena of available selective RET inhibitors and more data being released on emerging therapies, the landscape for patients with RET-positive metastatic NSCLC is evolving rapidly. Join Drs. Mark Socinski and Justin Gainor as they review the importance of molecular testing in every patient, as well as when to initiate the use of selective RET-inhibitors across multiple lines of therapy. Did we mention you should be testing every patient? Tune in to make sure you're identifying everyone who can benefit from these newer therapies.

CME credits: 0.25 Valid until: 17-12-2022 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-applying-the-right-therapy-to-the-right-patient-in-ret-positive-nsclc/13130/ With an expanding arena of available selective RET inhibitors and more data being released on emerging therapies, the landscape for patients with RET-positive metastatic NSCLC is evolving rapidly. Join Drs. Mark Socinski and Justin Gainor as they review the importance of molecular testing in every patient, as well as when to initiate the use of selective RET-inhibitors across multiple lines of therapy. Did we mention you should be testing every patient? Tune in to make sure you're identifying everyone who can benefit from these newer therapies.

Host: Mark Socinski, MD Guest: Justin Gainor With an expanding arena of available selective RET inhibitors and more data being released on emerging therapies, the landscape for patients with RET-positive metastatic NSCLC is evolving rapidly. Join Drs. Mark Socinski and Justin Gainor as they review the importance of molecular testing in every patient, as well as when to initiate the use of selective RET-inhibitors across multiple lines of therapy. Did we mention you should be testing every patient? Tune in to make sure you're identifying everyone who can benefit from these newer therapies.

Host: Jennifer Caudle, DO Guest: Mark Socinski, MD Dr. Mark Socinski from the AdventHealth Cancer Institute in Florida joins Dr. Jennifer Caudle to discuss a patient profile in the treatment of relapsed small cell lung cancer to help us better understand the burden of this disease and how to approach treating patients in the second-line setting with treatment options like ZEPZELCA.

Host: Mark Socinski, MD Guest: Edward B. Garon, MD, MS In the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC), when is an EGFR TKI not enough? Answer: When you don't have all of the information. Digging deeper into the specific EGFR mutations has led to advances in the dual blockade of VEGF and EGFR in the frontline setting. Join Drs. Mark Socinski and Edward Garon as they discuss the evolving role of EGFR and VEGF blockade based on clinical trial data. Find out how you can have an immediate impact on your patients by making targeted treatment decisions based on specific oncogenic driver mutations in NSCLC. Be sure to keep up with our experts because making the right choice is more critical than ever.

CME credits: 0.25 Valid until: 30-11-2022 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-all-about-antiangiogenics-and-tkis-current-roles-and-future-directions-in-egfr-mutant-nsclc/13019/ In the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC), when is an EGFR TKI not enough? Answer: When you don't have all of the information. Digging deeper into the specific EGFR mutations has led to advances in the dual blockade of VEGF and EGFR in the frontline setting. Join Drs. Mark Socinski and Edward Garon as they discuss the evolving role of EGFR and VEGF blockade based on clinical trial data. Find out how you can have an immediate impact on your patients by making targeted treatment decisions based on specific oncogenic driver mutations in NSCLC. Be sure to keep up with our experts because making the right choice is more critical than ever.

CME credits: 0.25 Valid until: 30-11-2022 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-how-would-you-treat-case-based-learning-in-egfr-mutant-nsclc/13067/ FLAURA and RELAY have changed the landscape of treatment in EGFR-mutant advanced non-small cell lung cancer (NSCLC). But how do know which patients will benefit from these important advances in our knowledge of treating these cancers in the first and subsequent lines of therapy? Join Drs. Mark Socinski and John Heymach as they examine a patient case and discuss the “art” of treatment selection and sequencing of therapy. They also dive into recent advances in the dual blockade of antiangiogenics and TKIs in the frontline setting. Tune in to keep up!

CME credits: 0.25 Valid until: 30-11-2022 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-how-would-you-treat-case-based-learning-in-egfr-mutant-nsclc/13067/ FLAURA and RELAY have changed the landscape of treatment in EGFR-mutant advanced non-small cell lung cancer (NSCLC). But how do know which patients will benefit from these important advances in our knowledge of treating these cancers in the first and subsequent lines of therapy? Join Drs. Mark Socinski and John Heymach as they examine a patient case and discuss the “art” of treatment selection and sequencing of therapy. They also dive into recent advances in the dual blockade of antiangiogenics and TKIs in the frontline setting. Tune in to keep up!

CME credits: 0.25 Valid until: 30-11-2022 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-all-about-antiangiogenics-and-tkis-current-roles-and-future-directions-in-egfr-mutant-nsclc/13019/ In the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC), when is an EGFR TKI not enough? Answer: When you don't have all of the information. Digging deeper into the specific EGFR mutations has led to advances in the dual blockade of VEGF and EGFR in the frontline setting. Join Drs. Mark Socinski and Edward Garon as they discuss the evolving role of EGFR and VEGF blockade based on clinical trial data. Find out how you can have an immediate impact on your patients by making targeted treatment decisions based on specific oncogenic driver mutations in NSCLC. Be sure to keep up with our experts because making the right choice is more critical than ever.

Host: Mark Socinski, MD Guest: John V. Heymach, MD, PhD FLAURA and RELAY have changed the landscape of treatment in EGFR-mutant advanced non-small cell lung cancer (NSCLC). But how do know which patients will benefit from these important advances in our knowledge of treating these cancers in the first and subsequent lines of therapy? Join Drs. Mark Socinski and John Heymach as they examine a patient case and discuss the “art” of treatment selection and sequencing of therapy. They also dive into recent advances in the dual blockade of antiangiogenics and TKIs in the frontline setting. Tune in to keep up!

As part of the OncView video series, CancerNetwork spoke with Mark Socinski, MD, of the AdventHealth Cancer Institute in Orlando, Florida about updates in the management of extensive-stage small cell lung cancer (ES-SCLC). Socinski touched on a number of important aspects of treating this disease, including the existing standards of care, treatment challenges, immunotherapy, IMpower 133 trial, and more. Don't forget to subscribe to the "Oncology Peer Review On-The-Go" podcast wherever you get your podcasts.

Host: Mark A. Socinski, MD Guest: Alexander Drilon, MD There are now multiple biomarker-defined patient subgroups in advanced non-small cell lung cancer (NSCLC), including RET rearrangements, and there is growing evidence that treatment with targeted therapies has significant clinical outcomes. In response to current rapid changes in the field of NSCLC, Drs. Mark Socinski and Alexander Drilon discuss the biology of RET fusion and how to translate the latest recommendations for targeted therapies into clinical practice.

Host: Mark A. Socinski, MD Guest: Alexander Drilon, MD There are now multiple biomarker-defined patient subgroups in advanced non-small cell lung cancer (NSCLC), including RET rearrangements, and there is growing evidence that treatment with targeted therapies has significant clinical outcomes. In response to current rapid changes in the field of NSCLC, Drs. Mark Socinski and Alexander Drilon discuss the biology of RET fusion and how to translate the latest recommendations for targeted therapies into clinical practice. Since this CME activity has been published the FDA has approved a new treatment for adults with metastatic RET fusion-positive non-small cell lung cancer. To learn more about this approval, please visit the FDA.gov: FDA approves pralsetinib for lung cancer with RET gene fusions

CME credits: 0.25 Valid until: 24-08-2021 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-advances-in-ret-fusion-positive-nsclc/11784/ There are now multiple biomarker-defined patient subgroups in advanced non-small cell lung cancer (NSCLC), including RET rearrangements, and there is growing evidence that treatment with targeted therapies has significant clinical outcomes. In response to current rapid changes in the field of NSCLC, Drs. Mark Socinski and Alexander Drilon discuss the biology of RET fusion and how to translate the latest recommendations for targeted therapies into clinical practice.

CME credits: 0.25 Valid until: 24-08-2021 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-advances-in-ret-fusion-positive-nsclc/11784/ There are now multiple biomarker-defined patient subgroups in advanced non-small cell lung cancer (NSCLC), including RET rearrangements, and there is growing evidence that treatment with targeted therapies has significant clinical outcomes. In response to current rapid changes in the field of NSCLC, Drs. Mark Socinski and Alexander Drilon discuss the biology of RET fusion and how to translate the latest recommendations for targeted therapies into clinical practice. Since this CME activity has been published the FDA has approved a new treatment for adults with metastatic RET fusion-positive non-small cell lung cancer. To learn more about this approval, please visit the FDA.gov: FDA approves pralsetinib for lung cancer with RET gene fusions

CME credits: 0.25 Valid until: 07-08-2021 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-lung-cancer-advances-first-line-therapy-egfr-mutated-nsclc/11773/ Advances in treatment and new insights into the biology of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) have led to the development of treatments that significantly extend overall survival. In this discussion, Drs. Mark Socinski and Helena Yu cover the latest scientific and clinical data on the emerging role of targeted therapies in EGFR mutation-positive NSCLC.

CME credits: 0.25 Valid until: 07-08-2021 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-lung-cancer-advances-first-line-therapy-egfr-mutated-nsclc/11773/ Advances in treatment and new insights into the biology of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) have led to the development of treatments that significantly extend overall survival. In this discussion, Drs. Mark Socinski and Helena Yu cover the latest scientific and clinical data on the emerging role of targeted therapies in EGFR mutation-positive NSCLC.

Host: Mark A. Socinski, MD Guest: Helena Yu, MD Advances in treatment and new insights into the biology of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) have led to the development of treatments that significantly extend overall survival. In this discussion, Drs. Mark Socinski and Helena Yu cover the latest scientific and clinical data on the emerging role of targeted therapies in EGFR mutation-positive NSCLC.

Host: Mark A. Socinski, MD Guest: Helena Yu, MD Advances in treatment and new insights into the biology of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) have led to the development of treatments that significantly extend overall survival. In this discussion, Drs. Mark Socinski and Helena Yu cover the latest scientific and clinical data on the emerging role of targeted therapies in EGFR mutation-positive NSCLC.

CME credits: 0.25 Valid until: 15-07-2021 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-lung-cancer-use-immunotherapy-mutation-positive-non-small-cell-lung-cancer/11723/ Advanced non-small cell lung cancer (NSCLC) remains incurable; however, advances in treatment and new insights into the molecular pathogenesis of the disease have led to the development of treatments that significantly extend overall survival. This discussion between Drs. Mark Socinski and Gilberto de Lima Lopes reviews the emerging scientific and clinical data on the role of immunotherapy in mutation-positive NSCLC. Tune in to discover how these therapeutics can benefit your patients.

CME credits: 0.25 Valid until: 15-07-2021 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-lung-cancer-use-immunotherapy-mutation-positive-non-small-cell-lung-cancer/11723/ Advanced non-small cell lung cancer (NSCLC) remains incurable; however, advances in treatment and new insights into the molecular pathogenesis of the disease have led to the development of treatments that significantly extend overall survival. This discussion between Drs. Mark Socinski and Gilberto de Lima Lopes reviews the emerging scientific and clinical data on the role of immunotherapy in mutation-positive NSCLC. Tune in to discover how these therapeutics can benefit your patients.

Host: Mark A. Socinski, MD Guest: Gilberto de Lima Lopes Junior, MD, MBA, FAMS Advanced non-small cell lung cancer (NSCLC) remains incurable; however, advances in treatment and new insights into the molecular pathogenesis of the disease have led to the development of treatments that significantly extend overall survival. This discussion between Drs. Mark Socinski and Gilberto de Lima Lopes reviews the emerging scientific and clinical data on the role of immunotherapy in mutation-positive NSCLC. Tune in to discover how these therapeutics can benefit your patients.

Host: Mark A. Socinski, MD Guest: Gilberto de Lima Lopes Junior, MD, MBA, FAMS Advanced non-small cell lung cancer (NSCLC) remains incurable; however, advances in treatment and new insights into the molecular pathogenesis of the disease have led to the development of treatments that significantly extend overall survival. This discussion between Drs. Mark Socinski and Gilberto de Lima Lopes reviews the emerging scientific and clinical data on the role of immunotherapy in mutation-positive NSCLC. Tune in to discover how these therapeutics can benefit your patients.

Host: Mark A. Socinski, MD Guest: Edward B. Garon, MD, MS Advanced non-small cell lung cancer (NSCLC) remains incurable, but overall survival is improving, as shown by new scientific and clinical data that are emerging on the use of checkpoint inhibitors in the frontline setting and after disease progression. This discussion between Drs. Mark Socinski and Edward Garon addresses the role of PD-L1 expression and reviews how the newer checkpoint inhibitors can be applied to clinical practice.

CME credits: 0.25 Valid until: 14-07-2021 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-lung-cancer-role-immunotherapy-after-disease-progression/11724/ Advanced non-small cell lung cancer (NSCLC) remains incurable, but overall survival is improving, as shown by new scientific and clinical data that are emerging on the use of checkpoint inhibitors in the frontline setting and after disease progression. This discussion between Drs. Mark Socinski and Edward Garon addresses the role of PD-L1 expression and reviews how the newer checkpoint inhibitors can be applied to clinical practice.

CME credits: 0.25 Valid until: 14-07-2021 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-lung-cancer-role-immunotherapy-after-disease-progression/11724/ Advanced non-small cell lung cancer (NSCLC) remains incurable, but overall survival is improving, as shown by new scientific and clinical data that are emerging on the use of checkpoint inhibitors in the frontline setting and after disease progression. This discussion between Drs. Mark Socinski and Edward Garon addresses the role of PD-L1 expression and reviews how the newer checkpoint inhibitors can be applied to clinical practice.

Host: Mark A. Socinski, MD Guest: Edward B. Garon, MD, MS Advanced non-small cell lung cancer (NSCLC) remains incurable, but overall survival is improving, as shown by new scientific and clinical data that are emerging on the use of checkpoint inhibitors in the frontline setting and after disease progression. This discussion between Drs. Mark Socinski and Edward Garon addresses the role of PD-L1 expression and reviews how the newer checkpoint inhibitors can be applied to clinical practice.

In this episode of “CURE Talks Cancer,” we spoke with Dr. Mark Socinski to learn more about stage 3 lung cancer and what others should know about the disease.

CME credits: 0.25 Valid until: 28-06-2020 Claim your CME credit at https://reachmd.com/programs/cme/practical-considerations-use-immune-checkpoint-inhibitors-and-chemotherapy-mnsclc/10812/ In this panel discussion, Dr. Mark Socinski sits down with Dr. Benjamin Levy and Dr. Jyoti Patel to discuss the ways we can use PD-L1 status to identify when monotherapy or combination therapy is appropriate in patients with newly diagnosed metastatic non-small cell lung cancer (mNSCLC).

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination with radiotherapy for stage III NSCLC.

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination with radiotherapy for stage III NSCLC.

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination with radiotherapy for stage III NSCLC.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.

Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.

Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.

Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.

Dr. Mark Socinski, University of Pittsburgh Medical Center, defines the three compartments in stage III (locally advanced) NSCLC, each of which must be treated.

Dr. Mark Socinski, University of Pittsburgh Medical Center, defines the three compartments in stage III (locally advanced) NSCLC, each of which must be treated.

Dr. Mark Socinski, University of Pittsburgh Medical Center, defines the three compartments in stage III (locally advanced) NSCLC, each of which must be treated.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.

Mark Socinski, MD, Director of the Lung Cancer Section at the University of Pittsburgh Medical Center, leads a case-based discussion on the contemporary management of non-small cell lung cancer.

Drs. Mark Socinski from Univ. of Pittsburgh and Joel Neal from Stanford Cancer Center answer questions about topics covered in the summary of lung cancer highlights from ASCO 2012.

Drs. Mark Socinski from Univ. of Pittsburgh and Joel Neal from Stanford Cancer Center answer questions about topics covered in the summary of lung cancer highlights from ASCO 2012.

Dr. Mark Socinski reviews key results in small cell lung cancer (SCLC) from ASCO 2012, including the SWOG 0802 trial of topotecan +/- VEGF inhibitor aflibercept and a Japanese randomized trial of cisplatin/amrubicin vs. cisplatin/irinotecan.

Dr. Mark Socinski reviews key results in small cell lung cancer (SCLC) from ASCO 2012, including the SWOG 0802 trial of topotecan +/- VEGF inhibitor aflibercept and a Japanese randomized trial of cisplatin/amrubicin vs. cisplatin/irinotecan.

Dr. Mark Socinski from University of Pittsburgh summarizes and critiques the TAILOR trial of Taxotere (docetaxel) vs. Tarceva (erlotinib) in EGFR wild type advanced NSCLC.

Dr. Mark Socinski from University of Pittsburgh summarizes and critiques the TAILOR trial of Taxotere (docetaxel) vs. Tarceva (erlotinib) in EGFR wild type advanced NSCLC.

Dr. Mark Socinski from the University of Pittsburgh reviews evidence to support doublet chemo over single agent for marginal performance status (PS2) patients with advanced NSCLC.

Dr. Mark Socinski from the University of Pittsburgh reviews evidence to support doublet chemo over single agent for marginal performance status (PS2) patients with advanced NSCLC.

Dr. Mark Socinski from the University of Pittsburgh reviews the survival benefit and implications from the PARAMOUNT maintenance therapy trial of Alimta (pemetrexed) in advanced NSCLC.

Dr. Mark Socinski from the University of Pittsburgh reviews the survival benefit and implications from the PARAMOUNT maintenance therapy trial of Alimta (pemetrexed) in advanced NSCLC.

Dr. Mark Socinski, medical oncologist and leader of the Thoracic Oncology Program at Univ. of North Carolina, answers questions about what treatments to recommend after first line therapy for advanced NSCLC and when they should be pursued.

Dr. Mark Socinski, medical oncologist and leader of the Thoracic Oncology Program at Univ. of North Carolina, answers questions about what treatments to recommend after first line therapy for advanced NSCLC and when they should be pursued.

Dr. Mark Socinski, medical oncologist and leader of the Thoracic Oncology Program at Univ. of North Carolina, summarizes the evidence and presents a current approach to managing treatment of advanced NSCLC after first line therapy.

Dr. Mark Socinski, medical oncologist and leader of the Thoracic Oncology Program at Univ. of North Carolina, summarizes the evidence and presents a current approach to managing treatment of advanced NSCLC after first line therapy.